Filter, analyze, and streamline your search for investment opportunities with TipRanks' Stock Screener.
According to TipRanks, Werber is a 5-star analyst with an average return of 9.3% and a 51.72% success rate. Werber covers the Healthcare sector, focusing on stocks such as Genmab, Springworks Therapeutics, and Exelixis.
Relay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $18.17.
Based on Relay Therapeutics' latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $88.11 million. In comparison, last year the company earned a revenue of $25.2 million and had a GAAP net loss of $65.73 million
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RLAY in relation to earlier this year. Earlier this month, Sanjiv Patel, the President & CEO of RLAY sold 215,506.00 shares for a total of $818,399.50.